🟢 SAB Biotherapeutics is trading 5% up in pre-market with no clear company-specific catalyst identified

SAB Biotherapeutics is trading at $3.40, up 5.26%, in pre-market, with no clear company-specific catalyst identified.

• The latest company announcement schedules third-quarter results for November 5, 2026; it does not report results today.
• The October 13 FDA Fast Track announcement predates the move and does not establish its cause.
• Broader markets, including the Nasdaq, are weak, and available evidence does not point to a same-direction market explanation. Premarket volume or activity details were unavailable.